Scientific Update Laxman Bahroo, MD
|
|
- Amelia McCormick
- 5 years ago
- Views:
Transcription
1 Scientific Update Laxman Bahroo, MD Associate Professor Director; Botulinum Toxin Clinic Director; Neurology Residency Program Medstar Georgetown University Hospital Washington, D.C.
2 Disclosures Advisory Board and Consultant/independent contractor: Allergan plc, Acadia Pharmaceuticals, Inc., Cynapsus Therapeutics, Inc., Ipsen Biopharmaceuticals, Inc., Lundbeck, Teva Pharmaceuticals, and US WorldMeds LLC. Speaker s Bureau participant: AbbVie Inc., Allergan plc, Acadia Pharmaceuticals, Inc., Ipsen Biopharmaceuticals, Inc., Lundbeck, Teva Pharmaceuticals, UCB, and US WorldMeds LLC.
3 Objectives 1. Discuss the structure and function of botulinum toxin 2. Briefly review history 3. Review current botulinum toxin products available in US 4. Discuss study comparing multiple preparations 5. Discuss ongoing studies for botulinum toxins and future indications **Discussion of off label uses of botulinum toxins
4 Botulinum Toxin Structure 7 serotypes A G found in nature Heavy Chain and light chain complex held by disulfide bonds Accessory proteins: hemaggluttinin and nonhemaggluttinin proteins Manual of Botulinum Toxin Therapy. Cambridge University Press; 2 edition (March 31, 2014)
5 Botulinum Toxin Structure Light Chain (enzyme) Light Chain (50 kd) Heavy Chain delivery/binding Heavy Chain (100 kd) Available:
6
7
8 History of Botulinum Toxin Justinus Kerner MD Studied botulism, known as sausage poisoning Botulus is Latin for sausage Published 2 monographs on the effect of botulism and found the causes of death to be cardiac failure or respiratory arrest The capacity of nerve conduction is interrupted by the toxin in the same way as in an electric conductor by rust Manual of Botulinum Toxin Therapy. Cambridge University Press; 2 edicon (March 31, 2014).
9 From Poison to Therapeutic Agent Clostridium botulinum linked to botulism Crude form of type A isolated by Herman Sommer, MD Botulinum toxins shown to block neuromuscular transmission BoNT-A: Preclinical research by Allan Scott and Edward Schantz MD BoNT-A: First experimental use in humans by Allan Scott, MD s FDA approves Glabellar lines 2002 FDA approves Primary Axillary Hyperhydrosis FDA approves Dysport 1920s s Botox & Myobloc FDA approved for Cervical Dystonia FDA approves ULS & Chronic Migraine New formulation of Botox (low protein) FDA Approved 1997 FDA approves Xeomin 2011 NDO Overactive Bladder FDA approves Botox for Strabismus & blepharospasm
10 Various Preparations of Botulinum Toxins Available:
11 Unique Names for Botulinum Toxins Onabotulinum toxin A Botox Abobotulinum toxin A Dysport Incobotulinum toxin A Xeomin Rimabotulinum toxin B Myobloc Using brand names as they are easier to mention and more recognized.
12 Comparison of US Toxin Formulations Botox Dysport Xeomin Myobloc OnabotulinumtoxinA AbobotulinumtoxinA IncobotulinumtoxinA RimabotulinumtoxinB Vacuum Drying Lyophilization Lyophilization Soluble (500 units / 0.1ml) 900 kd complex 300 /600 kd complex 150 kd 600 kd 100 unit 300 unit 50 unit 2500 unit 200 unit 500 unit 100 unit 5000 unit units
13 Comparison of US Toxin Formulations Botox OnabotulinumtoxinA Dysport AbobotulinumtoxinA Xeomin IncobotulinumtoxinA Myobloc RimabotulinumtoxinB SNAP-25 SNAP-25 SNAP-25 VAMP Cosmetic Chronic Migraine Cosmetic Cervical Dystonia Cosmetic Blepharospasm Cervical Dystonia Blepharospasm Cervical Dystonia Cervical Dystonia ULS Neurogenic and non neurogenic Overactive Bladder
14 Benefits of Multiple Preparations Multiple options for patients Increased funding for scientific and clinical research Increased disease states studied Improved patient access to botulinum toxin therapy
15 Multiple Preparations 4 commercially available botulinum toxins in the United States Differences in purification process 1 units is LD50 and is based on proprietary assay (no standardized assay available) Each toxin has a unique dosing range Food & Drug Administration Conversion: Units / doses of each toxin formulation are unique and non-interchangeable Conversion table or ratio are strongly discouraged Black Box Warning Potentially life threatening distant toxin spread after local injection REMS (Risk Evaluation Mitigation Strategy) for patients to understand risk
16 A Study Evaluating Multiple Botulinum Toxin Preparations? Blepharospasm: long-term treatment with either Botox, Xeomin or Dysport. Kollewe K, Mohammadi B, Köhler S, Pickenbrock H, Dengler R, Dressler D. J Neural Transm (Vienna) Mar;122(3):
17 Study Overview 288 patients with blepharospasm 3 toxin preparations: Botox, Dysport and Xeomin Botox and Xeomin 4 units / 0.1ml Dysport 10 units / 0.1ml Evaluated toxin dose, dose ratio Reviewed latency, duration and response Reviewed adverse events across toxins 17
18 Results 18
19 Results 19
20 Lessons From the Study Various Botulinum toxins effectively manage blepharospasm Slight variability in latency and duration but not statistically significant No significant variability in side effects across multiple preparations Significant differences in dosing and dilution Key point: To use botulinum toxins effectively you must be familiar with dose and dilution 20
21 On Label Conditions Treated with Botulinum Toxin On Label On Label Continued 2 placebo controlled trials showing benefit Blepharospasm Cosmetic Hyperhidrosis Strabismus Hemifacial Spasm* Cervical Dystonia Chronic Migraine Upper Limb Spasticity Neurogenic Detrusor Overactivity Detrusor Overactivity
22 Off Label Conditions Treated with Botulinum Toxin Lack 2 placebo controlled trials but there is medical evidence showing benefit Various dystonias Lower Limb Spasticity Pediatric indications Pain syndromes Bruxism Achalasia There are more off label uses of botulinum toxins than on label uses
23 Emerging Indications - Overview Spasticity Upper Limb Lower Limb Pediatric Upper Limb Pediatric Lower Limb Sialorrhea Adolescent Chronic Migraine Neurogenic Detrusor Overactivity Reference for data on subsequent slides:
24 Upper Limb Spasticity (ULS) Botox approved in 2010 Biceps, FCU, FCR, FDS, FDP Dose 360 units Additional muscles approved in 2015 (NEW) Adductor Pollicus and Flexor Pollicus Longus Final Dose 400 units Botox Prescribing InformaCon. Available: hnps://
25 Botox Prescribing InformaCon. Available: hnps://
26 Dysport Upper Limb Spasticity approved in 2015 (NEW) Initial: Placebo vs 500 units vs 1000 units Extension: 500 units vs 1000 units Primary outcome: Modified Ashworth Secondary outcome: Physician Global Impression, Range of motion Dysport Prescribing InformaCon. Available: h"p://dysporthcp.com/adult-uls-efficacy.
27 Muscles and Dosing Dysport Prescribing InformaCon. Available: h"p://dysporthcp.com/adult-uls-efficacy.
28 Xeomin Upper Limb Spasticity (ULS) Approved 2015 (NEW) Placebo vs 400 units Endpoints: Primary Modified Ashworth Scale, Secondary Physician Global Assessment
29 Xeomin Prescribing InformaCon. Available: hnp://
30 Xeomin Prescribing InformaCon. Available: hnp://
31 Botox Lower Limb Spasticity (LLS) Approved in 2016 (NEW) Placebo vs units Endpoint: Primary: Modified Ashworth Scale Secondary: Pain scale, CGI, Goal attainment score (6 points)
32 Botox Prescribing InformaCon. Available: hnps://
33 Botox Prescribing InformaCon. Available: hnps://
34 Dysport Lower Limb Spasticity (LLS) Initial: Placebo vs 1000 units vs 1500 units Extension: 1000 units vs 1500 units (upper and lower) Endpoints: Primary: Modified Ashworth Scale Secondary: CGI, assessment of walking speed Status: Completion of Initial in May 2014 Status: Completion of Extension in late 2015
35 Lower Limb Spasticity Xeomin Placebo vs 400 units Endpoints: Modified Ashworth and CGI Status: Completed - results not available
36 Pediatric Upper Limb Spasticity Botox Placebo vs 3 units /Kg vs 6 units /Kg Age: 2 16 years with cerebral palsy or stroke Exclusion < 10 Kg, previous tendon lengthening surgery or planned surgery Endpoints: Primary: Modified Ashworth Secondary: CGI, Modified Tardieu Status: Completion 2017
37 Pediatric Upper Limb Spasticity Dysport 2 units /Kg vs 8units /Kg vs 16 units/kg Age: 2 17 years with cerebral palsy Inclusion: MAS 2 or greater, elbow, wrist hyper flexion Exclusion < 10 Kg, previous tendon lengthening surgery or planned surgery Endpoints: Primary: Modified Ashworth Secondary: CGI, Modified Tardieu Status: December 2016
38 Pediatric Lower Limb Spasticity Dysport Approved August 2016 (NEW) Study: Initial: Placebo vs 10 units/kg vs 15 units /Kg Extension: 10 units/kg up to 30 units/kg, not exceed 1000 units overall Endpoint: Primary: Modified Ashworth Secondary: CGI, Progress to goal
39 Dysport Pediatric Dosing Dysport Prescribing InformaCon. Available: h"p://dysporthcp.com/adult-uls-efficacy.
40 Pediatric Lower Limb Spasticity Botox Placebo vs 4 units /Kg vs 8 units/kg Age: 2 16 years with cerebral palsy or stroke Exclusion < 10 Kg, previous tendon lengthening surgery or planned surgery Endpoints: Primary: Modified Ashworth Secondary: CGI, Modified Tardieu Status: Completion 2017
41 Myobloc Sialorrhea Phase 3 multicenter trial Evaluating sialorrhea in adults Injections done with surface landmark guidance, ultrasound Placebo vs 2 doses Status: Completion late 2016
42 Xeomin Sialorrhea Phase 2 Placebo vs units Parkinson s disease, Parkinsonism, ALS Endpoints: Measure saliva volume and change in saliva volume at 1 month between placebo and active group Status: Completed November 2013
43 Chronic Migraine Botox approved for Adults with Chronic Migraine Botox study in Adolescents with Chronic Migraine Placebo vs 2 Doses Inclusion: years of age with Chronic Migraine Status: Recruitment complete Expected completion in late 2016
44 Chronic Migraine Endpoints: Primary: Change from baseline in the frequency of headache days Secondary: Change from baseline in the frequency of severe headache days Change from baseline in the total cumulative hours of headache on headache days Percentage of patients with 50% decrease from baseline in the frequency of headache days Percentage of patients who are prescribed oral rescue migraine prophylactic treatment
45 Neurogenic Detrusor Overactivity (NDO) Botox Approved for Neurogenic Detrusor Overactivity in 2011 Approved for Detrusor Overactivity in 2013 Botox study to evaluate role in pediatric neurogenic detrusor overactivity Placebo vs 3 dosing arms Status: Completion: June 2017
46 Pediatric Neurogenic Detrusor Overactivity (NDO) Endpoints: Primary: Change from Baseline in Daily Average Frequency of Daytime Urinary Incontinence Episodes Secondary: Change from Baseline in Maximum Cystometric Capacity (MCC) Percentage of Patients With Involuntary Detrusor Contractions (IDC) Change from Baseline in Maximum Detrusor Pressure During the First IDC Change from Baseline in Detrusor Leak Point Pressure (DLPP) Change from Baseline in Average Urine Volume at First Morning Catheterization Percentage of Patients With Night Time Urinary Incontinence Change from Baseline in Maximum Detrusor Pressure Time to Patient Request for Retreatment Time to Patient Qualification for Retreatment
47 Neurogenic Detrusor Overactivity (NDO) Dysport Phase 3 Trial Patients with MS or spinal Cord injury Dose: Placebo vs 600 units and 800 units End Points: Status: Completion 2021
48 Timeline of Approvals Estimated Approvals Based on phase 3 trials meeting primary endpoints without safety concerns and no issues with FDA approval process LLS Botox Pediatric LLS Dysport LLS Dysport
49 Timeline of Approvals Estimated Approvals continued Pediatric LLS Botox Sialorrhea Myobloc Pediatric ULS Dysport Adolescent Chronic Migraine Botox 2019 Pediatric NDO Botox 2021 NDO - Dysport
50 Summary Numerous Phase 3 trials currently underway Several potential upcoming indications in the next 4 years As botulinum toxin indications expand there will increased scrutiny As the use of botulinum toxins expands there will be increased need for training and education for safe and effective use.
51 Thank You!!
Botox. Botox (onabotulinum toxin A) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.01 Subject: Botox Page: 1 of 8 Last Review Date: September 15, 2017 Botox Description Botox (onabotulinum
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other ONABOTULINUMTOXINA BOTOX 04867 BRAND BOTOX COSMETIC ABOBOTULINUMTOXINA DYSPORT 36477 RIMABOTULINUMTOXINB MYOBLOC 21869 INCOBOTULINUMTOXINA XEOMIN 36687 Please use
More informationBotox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb)
Botox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date:
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH MICHIGA Botulinum Toxins (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationBOTOX. Description. Section: Prescription Drugs Effective Date: January 1, 2013 Subsection: CNS Original Policy Date: December 7, 2011
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.12.01 Subject: Botox Page: 1 of 6 Last Review Status/Date: December 6, 2012 BOTOX Description Botox (onabotulinum
More informationMEDICATION GUIDE BOTOX BOTOX Cosmetic (Boe-tox) (onabotulinumtoxina) for Injection
17.2 Ability to Operate Machinery or Vehicles Advise patients that if loss of strength, muscle weakness, blurred vision, or drooping eyelids occur, they should avoid driving a car or engaging in other
More informationAlbert C. Clairmont, MD Associate Professor-Clinical Department of PM & R The Ohio State University
Botulinum Toxin for Movement Disorders: Physiology, Pharmacology and Evaluation of Patients Albert C. Clairmont, MD Associate Professor-Clinical Department of PM & R The Ohio State University OBJECTIVES
More informationNeuromuscular Blocking Agents
Neuromuscular Blocking Agents DRUG POLICY This Prior Authorization request will be reviewed for medical necessity only. Benefits are subject to the terms and conditions of the patient s contract. Please
More informationBotox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb)
Botox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective
More informationBOTOX (onabotulinumtoxina) for Therapeutic Use
BOTOX (onabotulinumtoxina) for Therapeutic Use BOTOX (onabotulinumtoxina) & BOTOX Cosmetic (onabotulinumtoxina) Important Information IMPORTANT SAFETY INFORMATION BOTOX and BOTOX Cosmetic may cause serious
More informationCircle Yes or No Y N. [If yes, no further questions.]
02/18/2016 Prior Authorization AETA BETTER HEALTH PE MEDICAID & AETA BETTER HEALTH KIDS Botulinum Toxins (PA88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationClare Gaduzo BSc RMN Registered Aesthetics Practitioner (qualified with Medics Direct)
Clare Gaduzo BSc RMN Registered Aesthetics Practitioner (qualified with Medics Direct) 07935567067 cjg.aesthetics@yahoo.co.uk www.cjgaesthetics.co.uk http://www.facebook.com/cjgaesthetics @CJGAesthetics
More informationAetna Better Health of Virginia
Botox (onabotulinumtoxina) Myobloc (rimabotulinumtoxinb) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Indications: (use if necessary): Overactive Bladder BOTOX indicated for the treatment
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization MERC CARE PLA (MEDICAID) Botulinum Toxins (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationBotulinum toxins: abobotulinumtoxina (Dysport ), incobotulinumtoxina (Xeomin ), onabotulinumtoxina (Botox ), & rimabotulinumtoxinb (Myobloc )
Botulinum toxins: abobotulinumtoxina (Dysport ), incobotulinumtoxina (Xeomin ), onabotulinumtoxina (Botox ), & rimabotulinumtoxinb (Myobloc ) These services may or may not be covered by your HealthPartners
More informationBotox. Botox (onabotulinum toxin A) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.01 Subject: Botox Page: 1 of 10 Last Review Date: November 30, 2018 Botox Description Botox (onabotulinum
More informationBotulinum Toxin Therapy Billing & Coding Update 2016
Botulinum Toxin Therapy Billing & Coding Update 2016 Martin Taylor, DO, PhD Neurology / OrthoNeuro Clinical Associate Professor, Neurology Ohio University College of Osteopathic Medicine Columbus, OH Disclosures
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement Until 4/2/19. IncobotulinumtoxinA
IncobotulinumtoxinA NDC CODE(S) 00259-1605-XX Xeomin 50 UNIT SOLR (MERZ PHARMACEUTICAL) 00259-1610-XX Xeomin 100 UNIT SOLR (MERZ PHARMACEUTICAL) 00259-1620-XX Xeomin 200 UNIT SOLR (MERZ PHARMACEUTICAL)
More informationTable of Contents. 1.0 Description of the Procedure, Product, or Service Safety and Provider Compliance... 1
Table of Contents 1.0 Description of the Procedure, Product, or Service... 1 1.1 Safety and Provider Compliance... 1 2.0 Eligibility Requirements... 1 2.1 Provisions... 1 2.1.1 General... 1 2.1.2 Specific...
More informationProf. of Neurology, Cairo University Vice President of the Egyptian Society of Neurology, Secretary General of Pan Arab union of Neurological
Prof. of Neurology, Cairo University Vice President of the Egyptian Society of Neurology, Secretary General of Pan Arab union of Neurological Societies The Egyptian Society of Neurology, Psychiatry and
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Botulinum Toxins Reference Number: TCHP.PHAR.1812 Effective Date: 07.01.2018 Last Review Date: 04.13.2018 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the
More information(ONABOTULINUMTOXINA) RECEIVES U.S
BOTOX (ONABOTULINUMTOXINA) RECEIVES U.S. FDA APPROVAL FOR THE TREATMENT OF URINARY INCONTINENCE IN ADULTS WITH NEUROLOGICAL CONDITIONS INCLUDING MULTIPLE SCLEROSIS AND SPINAL CORD INJURY Clinical Trials
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: botulinum_toxin_injection 8/1985 10/2017 10/2018 10/2017 Description of Procedure or Service Description
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: botulinum_toxin_injection 8/1985 10/2015 10/2016 10/2015 Description of Procedure or Service Description
More informationLinks in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.
Local Coverage Determination (LCD): Drugs and Biologicals: Botulinum Toxins (L34253) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information
More information[If yes, no further questions.]
05/30/2014 Prior Authorization AETA BETTER HEALTH OF ILLIOIS MEDICAID Botox (IL88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationBOTOX Cosmetic (onabotulinumtoxina) before-and-after photo files
BOTOX Cosmetic (onabotulinumtoxina) before-and-after photo files INSTRUCTIONS FOR USE This zip file contains PDF files with images and Important Safety Information to copy and paste into your practice
More informationDRUG USE EVALUATION: UTILIZATION OF BOTULINUM TOXIN
There are currently four botulinum toxin (BoNT) products available in the United States: abobotulinumtoxina (ABO), incobotulinumtoxina (INC), onabotulinumtoxina (ONA), and rimabotulinumtoxinb (RIM). They
More informationBOTOX Cosmetic (onabotulinumtoxina) before-and-after
BOTOX Cosmetic (onabotulinumtoxina) before-and-after Moderate to severe crow s feet lines Before After (Day 7) Actual patient. Results may vary. Photos taken at full smile before and after treatment with
More informationThis policy addresses only the type B formulation rimabotulinumtoxinb marketed as Myobloc.
RimabotulinumtoxinB NDC CODE(S) 10454-0710-XX Myobloc 2500 UNIT/0.5ML SOLN (SOLSTICE NEUROSCIENCES) 10454-0711-XX Myobloc 5000 UNIT/ML SOLN (SOLSTICE NEUROSCIENCES) 10454-0712-XX Myobloc 10000 UNIT/2ML
More informationTHE CLINICAL USE OF BOTULINUM TOXIN IN THE TREATMENT OF MOVEMENT DISORDERS, SPASTICITY, AND SOFT TISSUE PAIN
THE CLINICAL USE OF BOTULINUM TOXIN IN THE TREATMENT OF MOVEMENT DISORDERS, SPASTICITY, AND SOFT TISSUE PAIN Spasmodic torticollis (cervical dystonia), blepharospasm, and writer s cramp are specific types
More informationAbbreviated Class Review: Botulinum toxins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationClinical Policy: IncobotulinumtoxinA (Xeomin) Reference Number: CP.PHAR.231
Clinical Policy: (Xeomin) Reference Number: CP.PHAR.231 Effective Date: 07/16 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationThis policy addresses only the type A formulation abobotulinumtoxina marketed as Dysport.
AbobotulinumtoxinA NDC CODE(S) 00299-5962-xx Dysport 300 UNIT VIAL (GALDERMA LABORA) 15054-0500-XX Dysport 500 UNIT SOLR (IPSEN BIOPHARMACEUTICALS) 15054-0530-XX Dysport 300 UNIT SOLR (IPSEN BIOPHARMACEUTICALS)
More informationOriginal Policy Date
MP 5.01.03 Botulinum Toxin Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index
More informationBotulinum Toxin. When Policy Topic is covered The use of botulinum toxin may be considered medically necessary for the following:
Botulinum Toxin Policy Number: 5.01.05 Last Review: 01/2018 Origination: 02/1998 Next Review: 02/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for botulinum toxin
More informationMedication Prior Authorization Form
(OnabotulinumtoxinA) Dysport (abobotulinumtoxina) Myobloc (rimabotulinumtoxinb) Xeomin (incobotulinumtoxina) Policy Number: 1042 Policy History Approve Date: 12/11/2015 Revise Dates: 7/7/2016 Next Review:
More informationWARNING: DISTANT SPREAD OF TOXIN EFFECT
Dear Doctor, We have enclosed a sample XEOMIN (incobotulinumtoxina) treatment patient consent form for your information. Please be aware that this form is merely intended for use as an example. Merz Aesthetics,
More informationPolicy. covered. (spasmodic. Cervical dystonia. injury, or more of. migraine. agents. - Migraine - Migraine. per month. communication, dystonia
Botulinum Toxin Policy Number: 5.01.05 Origination: 02/1998 Last Review: 02/2014 Next Review: 02/2015 Policy BCBSKC will provide coverage for botulinum toxin A and B injections it is determined to be medically
More informationSee Policy CPT/HCPCS CODE section below for any prior authorization requirements
Effective Date: 4/1/2017 Section: MED Policy No.: 209 Medical Officer 4/1/2018 Date Technology Assessment Committee Approved Date: 4/09;6/10, 01/11; 5/13; 2/15 Medical Policy Committee Approved Date: 11/09;
More informationDYSrupt Your Patients Spasticity Symptoms
The Dysport Profiles RALPH PATRICIA In the treatment of upper limb spasticity and lower limb spasticity in adults DYSrupt Your Patients Spasticity Symptoms Not actual patients In clinical trials with Dysport,
More informationAntibody-Induced Failure of Botulinum Toxin A Therapy in Cosmetic Indications
Antibody-Induced Failure of Botulinum Toxin A Therapy in Cosmetic Indications DIRK DRESSLER, MD, PHD, KAI WOHLFAHRT, MD, PHD, y ELLEN MEYER-ROGGE, MD, z LUITGARD WIEST, MD, y AND HANS BIGALKE, MD, PHD
More informationClinical Policy: Botulinum Toxins Reference Number: NE.PHAR.15
Clinical Policy: Reference Number: NE.PHAR.15 Effective Date: 01/01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationTreatment Framework patient tracker
Treatment Framework patient tracker Utilize the BOTOX Treatment Framework when evaluating your Focal Spasticity patients to establish The right goals The right muscles/dose The right plan Use the following
More informationLinks in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.
Local Coverage Determination (LCD): Botulinum Toxins (L33274) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information CONTRACTOR NAME
More informationPharmacy Medical Necessity Guidelines: Botulinum Toxins
Pharmacy Medical Necessity Guidelines: Effective: January 1, 2018 Effective: Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical
More informationBOTULINUM TOXINS A AND B
DRUG POLICY BOTULINUM TOXINS A B Policy Number: 2014D0017N Effective Date: 9/1/2014 Table of Contents Page COVERAGE RATIONALE... 1 BENEFIT CONSIDERATIONS... 7 BACKGROUND... 8 CLINICAL EVIDENCE... 8 U.S.
More informationBOTULINUM TOXIN POLICY TO INCLUDE:
BOTULINUM TOXIN POLICY TO INCLUDE: Blepharospasm in adults, Hemi facial spasm in adults, spasmodic torticollis (cervical dystonia), focal spasticity treatment of dynamic equinus foot deformity, focal spasticity
More informationHeadache and Migraine Treatment
Many of us think of Botox primarily as a cosmetic treatment for lines and wrinkles on the face, but the botulinum toxin that Botox is derived from has a long history of medically therapeutic uses. In fact,
More informationMEDICATION GUIDE Myobloc (My-o-block) (rimabotulinumtoxinb) Injection
MEDICATION GUIDE Myobloc (My-o-block) (rimabotulinumtoxinb) Injection Read the Medication Guide that comes with MYOBLOC before you start using it and each time MYOBLOC is given to you. There may be new
More informationMERZ NEUROSCIENCES to PRESENT XEOMIN (incobotulinumtoxina) DATA AT THE 21 ST INTERNATIONAL CONGRESS OF PARKINSON S DISEASE AND MOVEMENT DISORDERS
MERZ NEUROSCIENCES to PRESENT XEOMIN (incobotulinumtoxina) DATA AT THE 21 ST INTERNATIONAL CONGRESS OF PARKINSON S DISEASE AND MOVEMENT DISORDERS MERZ TO PRESENT FIVE POSTERS INCLUDING LATE BREAKER RALEIGH,
More informationA Treatment Guide for Adults With Upper Limb Spasticity
A Treatment Guide for Adults With Upper Limb Spasticity For the elbow, wrist, and fingers What you need to know about Dysport Dysport (abobotulinumtoxina) is a prescription medicine that is injected into
More informationElements of Provider Documentation Consistent with Medicare Guidelines
S T R E A M L I N E Elements of Provider Documentation Consistent with Medicare Guidelines 1 Document medical necessity Include a statement that BOTOX (onabotulinumtoxina) treatment is reasonable and necessary
More informationNAME OF THE MEDICINE BOTOX purified neurotoxin complex injection (50U, 100 U or 200 U) (botulinum toxin, type A) DESCRIPTION Composition
NAME OF THE MEDICINE BOTOX purified neurotoxin complex injection (50U, 100 U or 200 U) (botulinum toxin, type A) DESCRIPTION Composition Active ingredient: Each vial of BOTOX contains either 50 units (U),
More informationBOTULINUM TOXIN THERAPY FOR CERVICOGENIC HEADACHE AND NECK PAIN
BOTULINUM TOXIN THERAPY FOR CERVICOGENIC HEADACHE AND NECK PAIN Dr. Laxman Bahroo Director; Botulinum Toxin Clinic Director; Neurology Residency Program Associate Professor of Neurology Objectives Discuss
More informationBOTULINUM TOXINS A AND B
BOTULINUM TOXINS A AND B UnitedHealthcare Community Plan Medical Benefit Drug Policy Policy Number: CS2018D0017S Effective Date: January 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT
More informationInformed Consent Form
Informed Consent Form Botox Cosmetic (onabotulinumtoxin A) Dysport (abobotulinumtoxin A) Xeomin (incobotulinumtoxin A) INSTRUCTIONS This is an informed-consent document that has been prepared to help inform
More informationPrior Authorization Update: Botulinum Toxins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationBOTULINUM TOXINS A AND B
BOTULINUM TOXINS A AND B UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0017S Effective Date: January 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationFight spasticity with everything you ve got Let s talk about BOTOX
Fight spasticity with everything you ve got Let s talk about Indications is a prescription medicine that is injected into muscles to treat increased muscle stiffness in elbow, wrist, finger, thumb, ankle,
More informationBotulinum Toxin: Applications in Urology
Botulinum Toxin: Applications in Urology Dr. Lee Jonat, PGY-4 Department of Urologic Sciences University of British Columbia Outline Mechanism of Action Technical Considerations Adverse Events Neurogenic
More informationBotulinum Toxin Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: May 18, 2016 Renewal Date: August 16, 2017 Botulinum Toxin Drug Class Prior Authorization Protocol This policy has been developed through review of medical literature,
More informationDeveloping a Patient Welcome Letter BOTOX (onabotulinumtoxina) for appropriate patients
S T R E A M L I N E Developing a Patient Welcome Letter (onabotulinumtoxina) for appropriate patients Indications Bladder Dysfunction: Overactive Bladder for injection is indicated for the treatment of
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Botulinum Therapy Effective Date 1/15/2018 Next Review Date...1/15/2019 Coverage Position Number... 1106 Table of Contents Coverage Policy... 1 General Background...
More informationThe FIRST and ONLY FDA-APPROVED botulinum toxin for the treatment of LOWER LIMB SPASTICITY in pediatric patients 2 years of age and older 1.
The FIRST and ONLY FDA-APPROVED botulinum toxin for the treatment of LOWER LIMB SPASTICITY in pediatric patients years of age and older 5 Steps to dosing and dilution with Indication is indicated for the
More informationBotulinum Toxin Medical Policy Prior Authorization Program Summary
OBJECTIVE The intent of the botulinum toxin medical drug criteria is to ensure appropriate selection of patients for treatment according to product labeling and/or clinical studies and/or guidelines and
More informationDisclaimer. All information shared in this presentation is in the public domain.
THE BOTOX STORY Disclaimer All information shared in this presentation is in the public domain. Hence, no trade secret related to drug formulation, manufacturing process, commercial practice, etc. The
More informationTreatment Journal KEEPING TRACK OF DAILY MEDICATIONS: Medication. Started. Dosage. Doctor. Notes:
Treatment Journal KEEPING TRACK OF DAILY MEDICATIONS: It is very important to maintain a current list of your medications and the doses you take, and make copies to regularly update the medical records
More informationDr. F Didar CEO Cosmetic Facial UK(CFUK) Limited
Dr. F Didar CEO Cosmetic Facial UK(CFUK) Limited www.cosmeticfacial.co.uk, info@cosmeticfacial.co.uk 1. 1895:professor Emile Pierre Van Ermengem discovered(identified) bacterium bacillus botulinum. It
More informationBotulinum Toxins (BOTOX, DYSPORT, MYOBLOC and XEOMIN)
Botulinum Toxins (BOTOX, DYSPORT, MYOBLOC and XEOMIN) Policy Number: Original Effective Date: MM.04.004 03/14/2006 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 10/01/2013 Section: Prescription
More information& MIGRAINE DIARY YOUR HEADACHE. Talk with your doctor about BOTOX and Chronic Migraine
YOUR HEADACHE & MIGRAINE DIARY Do you really know how many headaches and migraines you have in a month? Keeping a diary like this one can help you find out. If you have 15 or more headache days a month,
More informationMedication Prior Authorization Form
(OnabotulinumtoxinA) Dysport (abobotulinumtoxina) Myobloc (rimabotulinumtoxinb) Xeomin (incobotulinumtoxina) Policy Number: 1042 Policy History Approve Date: 12/11/2015 Revise Dates: 07/07/2017 Next Review:
More informationDoctor discussion guide
Doctor discussion guide Start a conversation with your doctor today. These questions can help you and your doctor find out if you have Chronic Migraine (15 or more headache days a month with each headache
More information*Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada;
ORIGINAL ARTICLE The Convergence of Medicine and Neurotoxins: A Focus on Botulinum Toxin Type A and Its Application in Aesthetic Medicine A Global, Evidence-Based Botulinum Toxin Consensus Education Initiative
More informationParkinson's Disease Center and Movement Disorders Clinic
Parkinson's Disease Center and Movement Disorders Clinic 7200 Cambridge Street, 9th Floor, Suite 9A Houston, Texas 77030 713-798-2273 phone www.jankovic.org Botulinum Toxin Botulinum toxin (BTX) has been
More informationDrug Name (select from list of drugs shown / provide drug information) Patient Information. Prescribing Physician
Texas Standard Prior Authorization Form Addendum MOLINA TX MARKETPLACE Botulinum Toxins CL Molina Universal This fax machine is located in a secure location as required by HIPAA Regulations. Complete /
More informationBotulinium Type B is covered when filed with one of the indications listed in the attachment below( Botox B, ICD9 edits).
Medical Coverage Policy Botulinum Toxin Injection EFFECTIVE DATE: 09/17/2007 POLICY LAST UPDATED: 07/15/2014 OVERVIEW Botulinum toxin is produced by the anaerobic clostridium botulinum. Botulinum toxin
More informationClinical Policy: IncobotulinumtoxinA (Xeomin) Reference Number: ERX.SPA.194 Effective Date:
Clinical Policy: (Xeomin) Reference Number: ERX.SPA.194 Effective Date: 01.11.17 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationBotulinum toxin A (Dysport) for hyperhidrosis of the axillae
April 2016 Horizon Scanning Research & Intelligence Centre Botulinum toxin A (Dysport) for hyperhidrosis of the axillae LAY SUMMARY This briefing is based on information available at the time of research
More informationNAME OF THE MEDICINE. BOTOX purified neurotoxin complex injection (100 U or 200 U) (botulinum toxin, type A) DESCRIPTION.
NAME OF THE MEDICINE BOTOX purified neurotoxin complex injection (100 U or 200 U) (botulinum toxin, type A) DESCRIPTION Composition Active ingredient: Each vial of BOTOX contains either 100 units (U) or
More informationNeurotoxins (Botox, Dysport, Myobloc and Xeomin )
Last Review Date: November 10, 2017 Number: MG.MM.PH.01mC Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationBOTULINUM TOXIN IN LOWER URINARY TRACT
BOTULINUM TOXIN IN LOWER URINARY TRACT Selcuk Yucel, MD Professor in Urology and Pediatric Urology Acibadem University School of Medicine Department of Uroloy and Pediatric Urology Acibadem University
More informationBOTOX is the first and only preventive treatment proven to reduce headache days every month.
For adults with Chronic Migraine, 15 or more headache days a month, each lasting 4 hours or more, BOTOX is the first and only preventive treatment proven to reduce headache days every month. BOTOX prevents
More informationGETTING STARTED WITH BOTOX TREATMENT
GETTING STARTED WITH BOTOX TREATMENT BOTOX is a prescription medicine that is injected to prevent headaches in adults with Chronic Migraine who have 15 or more days each month with headache lasting 4 or
More informationFrustrated with your Overactive bladder (OAB) Medication? Can t tolerate the side effects? Ask your doctor about...
Frustrated with your Overactive bladder (OAB) Medication? Can t tolerate the side effects? Ask your doctor about... injection BOTOX treats the OAB symptoms of leakage, the strong sudden need to go, and
More informationWhy is this botulinum toxin prescribed?
Why is this botulinum toxin prescribed? Botulinum Toxin injections are in a class of medications called neurotoxins. When Botulinum Toxin is injected into a muscle, it blocks the nerve signals that cause
More informationCIC Edizioni Internazionali. Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal
Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal Adriano Ferrari, MD a Mario Manca, MD b Valeria Tugnoli, MD c Luigi Alberto Pini, MD
More informationTake Cervical Dystonia head on
Take Cervical Dystonia head on Indication is a prescription medicine that is injected into muscles and used to treat the abnormal head position and neck pain that happens with cervical dystonia (CD) in
More informationDystonias Peter McAllister, MD
Dystonias Peter McAllister, MD Medical Director, New England Institute for Neurology and Headache Chief Medical Officer, New England Institute for Clinical Research Clinical Assistant Professor, Neurology,
More informationFor each of your Focal Spasticity patients, establish... The right goals. The right muscles/dose
FOCAL SPASTICITY Treatment Framework For each of your Focal Spasticity patients, establish... The right goals The right plan The right muscles/dose Indications Spasticity: Upper Limb Spasticity for injection
More informationScottish Medicines Consortium
Scottish Medicines Consortium clostridium botulinum neurotoxin type A, 100 unit powder for solution for injection (Xeomin ) No. (464/08) Merz Pharma UK Ltd 09 May 2008 The Scottish Medicines Consortium
More informationPress release Ipsen announces publication in Neurology
Press release Ipsen announces publication in Neurology of results of two studies demonstrating the efficacy and safety of Dysport (abobotulinumtoxina) in adult patients with lower limb spasticity Results
More informationBotulinum Toxins. Length of Authorization: From 90 days to 12 months
Botulinum Toxins Goal(s): Approve botulinum toxins for funded OHP conditions supported by evidence of benefit (eg, dystonia or spasticity associated with certain neurological diseases). Require positive
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Clostridium botulinum neurotoxin type A haemagglutinin complex Pharmaceutical form(s)/strength: powder for solution for injection, 300 unit and 500 unit P-RMS:
More informationDrug Class Update: Botulinum Toxins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationIndependent prescribing by physiotherapists in neurological rehabilitation: Management of spasticity with botulinum toxin
London North West Healthcare NHS Trust Independent prescribing by physiotherapists in neurological rehabilitation: Management of spasticity with botulinum toxin Dr Stephen Ashford Regional Hyper-acute
More informationTreating Adults with Cervical Dystonia
Treating Adults with Cervical Dystonia Learn more about Dysport Talk to your doctor about Dysport and find out if it is right for you. What is Dysport? Dysport is a prescription medicine that is injected
More informationBotox Approval Process Orange County Migraine & Headache Center
Botox Approval Process Orange County Migraine & Headache Center Step One: Discuss with Dr. Hutchinson if Botox makes sense for you. Documentation of headache greater than 15 days a month is needed as well
More informationDOSAGE FORMS AND STRENGTHS For Injection: 100 Units or 200 Units vacuum-dried powder in a single-dose vial (3)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (onabotulinumtoxina) for injection,
More information